Terms: = Sarcomas AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR AND Treatment
12 results:
1. Revealing the pharmacological effects of Remodelin against osteosarcoma based on network pharmacology, acRIP-seq and experimental validation.
Gao J; Xu P; Wang F; Zhang W; Min M; Urba R; Fan L
Sci Rep; 2024 Feb; 14(1):3577. PubMed ID: 38347067
[TBL] [Abstract] [Full Text] [Related]
2. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Piha-Paul SA; Xu B; Dumbrava EE; Fu S; Karp DD; Meric-Bernstam F; Hong DS; Rodon JA; Tsimberidou AM; Raghav K; Ajani JA; Conley AP; Mott F; Fan Y; Fan J; Peng P; Wang H; Ni S; Sun C; Qiang X; Levin WJ; Ngo B; Ru QC; Wu F; Javle MM
Oncologist; 2024 Apr; 29(4):e514-e525. PubMed ID: 38297981
[TBL] [Abstract] [Full Text] [Related]
3. Molecular Profile of Intrahepatic Cholangiocarcinoma.
Andraus W; Tustumi F; de Meira Junior JD; Pinheiro RSN; Waisberg DR; Lopes LD; Arantes RM; Rocha Santos V; de Martino RB; Carneiro D'Albuquerque LA
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203635
[TBL] [Abstract] [Full Text] [Related]
4. FGF2 drives osteosarcoma metastasis through activating FGFR1-4 receptor pathway-mediated ICAM-1 expression.
Huang YC; Chen WC; Yu CL; Chang TK; I-Chin Wei A; Chang TM; Liu JF; Wang SW
Biochem Pharmacol; 2023 Dec; 218():115853. PubMed ID: 37832794
[TBL] [Abstract] [Full Text] [Related]
5. Gastric carcinosarcoma with fgfr2 amplification under long-term control with pazopanib: a case report and literature review.
Hayashi H; Makiyama A; Okumura N; Yasufuku I; Saigo C; Takeuchi T; Miyazaki T; Tanaka Y; Matsuhashi N; Murase K; Takahashi T; Futamura M; Yoshida K
BMC Gastroenterol; 2022 Jul; 22(1):360. PubMed ID: 35902814
[TBL] [Abstract] [Full Text] [Related]
6. Integrated DNA Copy Number and Expression Profiling Identifies IGF1R as a Prognostic Biomarker in Pediatric Osteosarcoma.
Taylor AM; Sun JM; Yu A; Voicu H; Shen J; Barkauskas DA; Triche TJ; Gastier-Foster JM; Man TK; Lau CC
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887382
[TBL] [Abstract] [Full Text] [Related]
7. Investigation of anticancer activities of STA-9090 (ganetespib) as a second generation HSP90 inhibitor in Saos-2 osteosarcoma cells.
Özgür A
J Chemother; 2021 Dec; 33(8):554-563. PubMed ID: 33794753
[TBL] [Abstract] [Full Text] [Related]
8. Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas.
Liu Y; Weber Z; San Lucas FA; Deshpande A; Jakubek YA; Sulaiman R; Fagerness M; Flier N; Sulaiman J; Davis CM; Fowler J; Starks D; Rojas-Espaillat L; Lazar AJ; Davies GE; Ehli EA; Scheet P
Gynecol Oncol; 2018 Nov; 151(2):243-249. PubMed ID: 30194005
[TBL] [Abstract] [Full Text] [Related]
9. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Chong DQ; Zhu AX
Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
[TBL] [Abstract] [Full Text] [Related]
10. fgfr2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.
Künstlinger H; Fassunke J; Schildhaus HU; Brors B; Heydt C; Ihle MA; Mechtersheimer G; Wardelmann E; Büttner R; Merkelbach-Bruse S
Oncotarget; 2015 Aug; 6(24):20215-30. PubMed ID: 26036639
[TBL] [Abstract] [Full Text] [Related]
11. Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance.
Monsma DJ; Cherba DM; Richardson PJ; Vance S; Rangarajan S; Dylewski D; Eugster E; Scott SB; Beuschel NL; Davidson PJ; Axtell R; Mitchell D; Lester EP; Junewick JJ; Webb CP; Monks NR
Pediatr Blood Cancer; 2014 Sep; 61(9):1570-7. PubMed ID: 24687871
[TBL] [Abstract] [Full Text] [Related]
12. Distinct patterns of expression of keratinocyte growth factor and its receptor in endometrial carcinoma.
Siegfried S; Pekonen F; Nyman T; Ammälä M; Rutanen EM
Cancer; 1997 Mar; 79(6):1166-71. PubMed ID: 9070494
[TBL] [Abstract] [Full Text] [Related]
